Dr. Till on the Potential to Utilize CAR T-Cell Therapy Earlier in MCL

Video

Brian Till, MD, discusses the potential to utilize CAR T-cell therapy earlier in the treatment of patients with mantle cell lymphoma.

Brian Till, MD, physician, Seattle Cancer Care Alliance, associate professor, Division of Medical Oncology, University of Washington School of Medicine, associate professor, Clinical Research Division, Fred Hutchinson Cancer Research Center, discusses the potential to utilize CAR T-cell therapy earlier in the treatment of patients with mantle cell lymphoma (MCL).

For some, the toxicities associated with CAR T-cell therapy may limit its utility for patients with MCL, says Till. Moreover, those who are uncomfortable with CAR T-cell therapy may prefer to reserve the therapy for third- or later-line use, Till explains.

However, the emergence of improved management strategies for cytokine release syndrome and neurotoxicity, as well as less toxic CAR T-cell products, could offer a greater level of comfort to utilize CAR T-cell therapy in the second-line setting for patients with MCL, particularly if mature data suggest the responses are durable, Till concludes.

Related Videos
Manali Kamdar, MD, on The Importance of Bringing Liso-Cel to Earlier Lines of Lymphoma Treatment
Subhash Tripathi, PhD, on Generating In Vivo CARs With A2-CAR-CISC EngTreg Cells
Luke Roberts, MBBS, PhD, on Challenges in Developing Gene Therapy for Heart Failure
Steve Kanner, PhD, the chief scientific officer of Caribou Biosciences
Paul Y. Song, MD, the chairman and chief executive officer of NKGen
Lisa Nieland on Slowing Tumor Growth in Glioblastoma With Novel AAV Therapy
Manali Kamdar, MD, on Acclimating to Routine CAR T Practice in the Field
Paul Y. Song, MD, the chairman and chief executive officer of NKGen
Jennifer Taylor-Cousar, MD, MSCS, on Early Signals of Efficacy With Cystic Fibrosis Gene Therapy
Leigh Ramos-Platt, MD, on Looking Forward to Gene Therapy’s Growth
© 2024 MJH Life Sciences

All rights reserved.